The United States has initiated a trade investigation into Germany, focusing on proposed German healthcare reforms aimed at reducing pharmaceutical prices. This action raises the possibility of the US imposing new tariffs on German goods. The investigation stems from concerns that Germany’s planned overhaul of its health system will disadvantage American pharmaceutical companies. Specifically, the US Trade Representative alleges the reforms may discriminate against US firms and violate trade agreements. Germany intends to negotiate drug prices collectively, a practice the US argues could limit market access for American manufacturers. The outcome of the investigation could significantly impact transatlantic trade relations and the pricing of prescription drugs. This probe reflects ongoing trade friction between the two nations and escalating concerns over pharmaceutical costs.